📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Loading analysis...
Aurobindo Pharma to Buyback Shares Worth ₹800 Crore at ₹1,475 Per Share
Aurobindo Pharma has announced a buyback of up to 54,23,728 equity shares via the tender offer route at a price of ₹1,475 per share. The total buyback size is ₹800 crore, representing approximately 0.93% of the total outstanding equity shares. The offer is scheduled to open on April 23, 2026, and close on April 29, 2026, for shareholders who held stock as of the April 17 record date. Small shareholders have been offered a favorable entitlement ratio of 7 shares for every 61 shares held.
Key Highlights
Buyback of 54,23,728 shares at a fixed price of ₹1,475 per share via tender route
Total outlay of ₹800 crore represents 2.62% of consolidated net worth as of March 2025
Entitlement ratio for small shareholders is 7:61; General category is 2:249
Offer period is set from April 23, 2026, to April 29, 2026
Settlement of bids expected to be completed by May 7, 2026
💼 Action for Investors
Eligible shareholders should consider tendering their shares to take advantage of the ₹1,475 buyback price, especially if it remains at a premium to the market price. Small shareholders should particularly note their higher entitlement ratio for potential short-term gains.
Loading analysis...
Aurobindo Pharma Receives USFDA Approval for OTC Cough Syrup; Market Size $138 Million
Aurobindo Pharma has secured final USFDA approval for Dextromethorphan Polistirex Extended-Release Oral Suspension (OTC), a generic version of Delsym. The product targets a US market valued at approximately $138 million for the 12 months ending February 2026. Production is slated for the APL Healthcare Unit-IV facility with a commercial launch expected in Q2FY27. This milestone increases the company's total USFDA approvals to 580, reinforcing its strong position in the US generic market.
Key Highlights
Final USFDA approval for Dextromethorphan Polistirex Extended-Release Oral Suspension (OTC) 30 mg/5 mL.
Addresses an estimated US market size of $138 million based on Nielsen data for the year ending Feb 2026.
Commercial launch is scheduled for Q2FY27 from the APL Healthcare Unit-IV facility.
Total USFDA portfolio now comprises 580 approvals, including 557 final and 23 tentative approvals.
💼 Action for Investors
This approval strengthens Aurobindo's US OTC pipeline and provides revenue visibility for FY27. Investors should maintain a positive outlook as the company continues to leverage its manufacturing scale to capture market share in the US generic space.
Loading analysis...
Aurobindo Pharma Receives USFDA Approval for Glycerol Phenylbutyrate; Market Size $50.2M
Aurobindo Pharma has received final USFDA approval for Glycerol Phenylbutyrate Oral Liquid (1.1 g/mL), a generic version of Ravicti. The product is indicated for the chronic management of patients with urea cycle disorders and will be launched immediately. The addressable market for this product is estimated at US$ 50.2 million for the twelve months ending February 2026. This approval further strengthens Aurobindo's extensive US portfolio, bringing its total USFDA ANDA approvals to 579.
Key Highlights
Final USFDA approval received for Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL.
Estimated annual market size of US$ 50.2 million according to IQVIA MAT February 2026 data.
The product will be manufactured at the company's Unit-III facility and launched immediately.
Aurobindo now holds a total of 579 ANDA approvals, including 556 final and 23 tentative approvals.
💼 Action for Investors
Investors should monitor the successful commercialization of this niche product as it contributes to the company's high-margin US generics business. The immediate launch and moderate market size provide a steady incremental revenue stream for the company.
Loading analysis...
Aurobindo Pharma Subsidiary to Invest $150-175M for 60KL Biologics Facility for MSD
Aurobindo Pharma's subsidiary, TheraNym Biologics, has expanded its contract manufacturing (CMO) agreement with Merck Sharp & Dohme (MSD) Singapore. The company will establish a greenfield project, 'Unit 2', involving an investment of USD 150 million to USD 175 million. This facility will house a large-scale mammalian Drug Substance manufacturing unit with a total capacity of 60,000 liters. This move significantly strengthens Aurobindo's footprint in the high-growth biologics CMO sector and deepens its strategic partnership with a global pharmaceutical leader.
Key Highlights
Investment of USD 150 million to USD 175 million for a new greenfield manufacturing facility
Installation of mammalian cell culture bioreactors with an aggregate capacity of 60,000 liters (60 KL)
Expansion of the existing CMO relationship with Merck Sharp & Dohme (MSD) initiated in May 2024
Development of 'Unit 2' to include requisite downstream purification infrastructure for Drug Substance production
💼 Action for Investors
Investors should view this as a strategic positive for long-term growth in the high-margin biologics space. Monitor the execution and commissioning timelines of the greenfield project as it represents a significant capital commitment.
Loading analysis...
Aurobindo Pharma Shareholders Approve Dr. Punita Kumar Sinha as Director with 98.96% Majority
Aurobindo Pharma Limited has announced the successful passage of a special resolution to appoint Dr. (Mrs.) Punita Kumar Sinha as an Independent Director. The resolution was passed via postal ballot with a significant majority of 98.96% of the votes cast in favor. The appointment is for a three-year term effective from February 9, 2026, to February 8, 2029. Total voter participation was high, with 513.4 million votes polled, representing 88.40% of the total equity shares.
Key Highlights
Special resolution for the appointment of Dr. Punita Kumar Sinha passed with 98.96% majority.
Total votes polled amounted to 513,445,001, representing 88.40% of the total share capital.
The appointment is for a fixed term of 3 consecutive years ending February 8, 2029.
Promoter and Promoter Group showed 100% voting participation and unanimous support for the resolution.
💼 Action for Investors
The high level of shareholder consensus for this appointment reflects strong confidence in the company's governance. Investors should view this as a routine but positive reinforcement of the board's independent oversight.
Loading analysis...
Aurobindo Pharma Subsidiary CuraTeQ Partners with STADA for Biosimilars in EU
CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, has entered into a marketing and distribution agreement with STADA Arzneimittel AG. The agreement covers two EMA-approved biosimilars developed by CuraTeQ for select European Union territories, including major markets like France and Germany. This partnership aims to leverage STADA's established distribution network to drive revenue growth and expand market reach for Aurobindo's biosimilar portfolio. Although the company classifies this as a non-material event, it represents a strategic move into the high-value European biologics market.
Key Highlights
Agreement with STADA Arzneimittel AG for marketing and distribution in select EU territories.
Focuses on two EMA-approved biosimilars developed by wholly owned subsidiary CuraTeQ Biologics.
Target markets include major European economies such as France and Germany.
New brand names will be created and registered specifically for each biosimilar product.
💼 Action for Investors
Investors should monitor the commercial launch and revenue ramp-up from these biosimilars as they represent a shift toward higher-margin complex products. This partnership validates the company's R&D capabilities in the biologics space.
Loading analysis...
Aurobindo Pharma's Unit-V API Facility Receives VAI Status from US FDA; Inspection Closed
Aurobindo Pharma's wholly owned subsidiary, Apitoria Pharma Private Limited, has received an Establishment Inspection Report (EIR) for its Unit-V API manufacturing facility in Telangana. The US FDA has classified the facility as 'Voluntary Action Indicated' (VAI) following an inspection conducted in December 2025. This classification effectively closes the inspection process which had previously resulted in three observations. This development is a positive step in maintaining regulatory compliance for the company's API production and ensures continued supply to the US market.
Key Highlights
US FDA inspected the Unit-V API facility from December 1 to December 12, 2025
The inspection initially resulted in a Form 483 with 3 observations
The facility has now been classified as Voluntary Action Indicated (VAI) by the US FDA
The US FDA has officially closed the inspection for this manufacturing unit
💼 Action for Investors
Investors should view this as a positive development that reduces regulatory uncertainty regarding the company's API supply chain. This clearance supports the company's manufacturing stability and export potential to the US.
Loading analysis...
Aurobindo Pharma's Eugia Unit-II Classified as OAI by US FDA Following 9 Observations
The US FDA has classified Unit-II of Eugia Pharma Specialities, a wholly-owned subsidiary of Aurobindo Pharma, as 'Official Action Indicated' (OAI). This follows an inspection conducted from November 3 to November 14, 2025, which resulted in 9 observations via Form 483. While the company states it does not foresee an immediate business impact, an OAI status typically delays new product approvals from the facility until regulatory concerns are addressed. Investors should monitor the remediation process closely as this facility is a key part of the company's specialty portfolio.
Key Highlights
US FDA classifies Eugia Pharma Unit-II in Bhiwadi, Rajasthan as 'Official Action Indicated' (OAI)
The classification follows an inspection conducted between November 3 and November 14, 2025
The inspection originally resulted in the issuance of a Form 483 with 9 specific observations
OAI status may lead to the withholding of new drug approvals (ANDAs) from this specific manufacturing site
Management currently anticipates no immediate material impact on existing business operations
💼 Action for Investors
Investors should exercise caution as OAI status can escalate to Warning Letters or Import Alerts if remediation is deemed insufficient. Monitor management commentary regarding the timeline for re-inspection and potential delays in the specialty product pipeline.
Loading analysis...
Aurobindo Pharma Faces ₹77.6 Cr GST Demand and Equal Penalty; To Appeal in GSTAT
Aurobindo Pharma has received an order from the GST Appellate Authority confirming a tax demand of ₹77.61 crore and an equivalent penalty of ₹77.61 crore. The dispute pertains to alleged excess IGST refunds and non-reversal of Input Tax Credit (ITC) for the period between July 2017 and March 2020. While the authority dropped the interest demand on ITC reversal, the primary tax and penalty were upheld. The company has already paid ₹23.72 crore under protest and intends to challenge the ruling at the GST Appellate Tribunal (GSTAT).
Key Highlights
GST demand of ₹77.61 crore confirmed along with a matching penalty of ₹77.61 crore.
Issues involve excess IGST refund (CIF vs FOB) and non-reversal of ITC under Rule 37 for FY 2017-2020.
Company has already deposited ₹23.72 crore under protest and reversed ₹8.78 crore in ITC.
Appellate Authority dropped the demand for interest on ITC reversal while upholding other charges.
Aurobindo Pharma plans to file an appeal before the Goods and Services Tax Appellate Tribunal (GSTAT).
💼 Action for Investors
Investors should monitor the outcome of the GSTAT appeal as the total potential liability exceeds ₹150 crore. While the company maintains there is no material impact, persistent tax litigation can weigh on short-term sentiment.
Loading analysis...
Aurobindo Pharma Subsidiary Unit-IV Receives VAI Status from US FDA
Aurobindo Pharma's wholly owned subsidiary, APL Healthcare Limited, has received an Establishment Inspection Report (EIR) for its Unit-IV facility in Andhra Pradesh. The US FDA has classified the facility as 'Voluntary Action Indicated' (VAI), effectively closing the inspection that took place in December 2025. This follows the initial issuance of a Form 483 with 5 observations at the conclusion of the audit. The VAI classification is a positive outcome, indicating that the regulatory hurdles for this specific unit are resolved for the current cycle.
Key Highlights
US FDA inspected APL Healthcare Unit-IV from December 8 to December 17, 2025
The inspection initially resulted in a Form 483 containing 05 observations
Facility has now been classified as Voluntary Action Indicated (VAI) by the US FDA
The receipt of the EIR signifies that the regulatory inspection for this unit is now officially closed
Unit-IV is located in SPSR Nellore District, Andhra Pradesh, and is a 100% subsidiary of Aurobindo Pharma
💼 Action for Investors
Investors should view this as a positive development as it clears a regulatory hurdle for a key manufacturing unit. This reduces compliance risk and paves the way for potential new product approvals from this facility.
Loading analysis...
Aurobindo Pharma Launches Generic Pomalyst in US Targeting $3.3 Billion Market
Aurobindo Pharma's wholly owned subsidiary, Eugia Pharma, has launched Pomalidomide Capsules in the US market. The product is a generic version of BMS Pharmaceuticals' Pomalyst, which has an estimated annual market size of $3.3 billion as of January 2026. As a First-to-File (FTF) applicant, Eugia is well-positioned to capture significant market share in this high-value oncology segment. The product will be manufactured at the company's Eugia Unit-I facility, supporting its specialty portfolio growth.
Key Highlights
Launched Pomalidomide Capsules in 1 mg, 2 mg, 3 mg, and 4 mg strengths in the US
Targets a substantial US market size of approximately $3.3 billion according to IQVIA MAT data
Eugia Pharma was one of the First-to-File (FTF) ANDA applicants for this product
The product is the generic equivalent of Pomalyst by BMS Pharmaceuticals Corp
Manufacturing will be handled at the Eugia Unit-I facility
💼 Action for Investors
Investors should monitor the market share gains in the US oncology segment as this launch represents a significant revenue opportunity. The FTF status provides a competitive edge that could bolster margins in the upcoming quarters.
Loading analysis...
Aurobindo Pharma Director P. Sarath Chandra Reddy Discharged in Delhi Liquor Case
Aurobindo Pharma has confirmed that its Non-Executive Director, Mr. P. Sarath Chandra Reddy, has been discharged by a Special CBI Court in the Delhi Liquor Excise Policy case. The court found no evidence of conspiracy, illegal gratification, or unlawful benefits involving Mr. Reddy after examining material from the CBI's supplementary chargesheet dated July 29, 2024. This discharge applies to all charges leveled by the CBI, effectively removing a significant legal and reputational overhang that had persisted since late 2022. The court specifically noted a lack of basis for including him as an accused in the case.
Key Highlights
Special CBI Court discharged Mr. P. Sarath Chandra Reddy and 22 others on February 27, 2026
Court found no material evidence of participation in conspiracy or payment of illegal gratification
Mr. Reddy was originally added as Accused No. 23 in a supplementary chargesheet dated July 29, 2024
The discharge follows two months of day-to-day arguments and extensive evidence examination
The court questioned the basis on which Mr. Reddy was arrayed as an accused in the first place
💼 Action for Investors
This is a positive development as it clears a key board member from a high-profile legal controversy, reducing corporate governance concerns. Investors can now focus back on the company's fundamental performance and USFDA compliance status.
Loading analysis...
Aurobindo Pharma Subsidiary Eugia Unit-I US FDA Inspection Ends with 4 Observations
The US FDA conducted a regulatory inspection at Unit-I of Eugia Pharma Specialities Ltd, a wholly owned subsidiary of Aurobindo Pharma, between February 16 and February 27, 2026. The inspection of this formulation manufacturing facility in Telangana concluded with 4 observations. The company intends to respond to these observations within the stipulated timelines and has stated there is no immediate impact on financials or operations. Investors should monitor the classification of these observations as they can influence future product approvals from this facility.
Key Highlights
US FDA inspection of Eugia Unit-I formulation facility took place from February 16 to February 27, 2026
The inspection concluded with 4 observations issued by the regulatory authority
Eugia Pharma Specialities Ltd is a 100% wholly owned subsidiary of Aurobindo Pharma Limited
Company confirms no current quantifiable impact on financials or operations due to the observations
💼 Action for Investors
Investors should wait for the US FDA's final classification of the inspection (NAI, VAI, or OAI) to determine the severity of the 4 observations. While the company claims no immediate impact, any escalation to a Warning Letter could affect the launch pipeline from this unit.
Loading analysis...
Aurobindo Pharma Subsidiary Receives USFDA Approval for Everolimus Tablets ($78M Market)
Aurobindo Pharma's wholly owned subsidiary, Eugia Pharma Specialities, has received final USFDA approval for Everolimus Tablets, a generic version of Novartis' Zortress. The approved product is indicated for the prophylaxis of organ rejection in kidney and liver transplant patients. The market size for this medication is estimated at approximately US$ 78 million for the 12 months ending December 2025. This approval marks the 184th ANDA for the Eugia group, with a commercial launch planned for Q1FY27.
Key Highlights
Final USFDA approval for Everolimus Tablets in 0.25 mg, 0.5 mg, 0.75 mg, and 1 mg strengths.
Estimated annual market size of US$ 78 million according to IQVIA MAT December 2025 data.
Commercial launch is expected to commence in Q1FY27 from the Eugia Unit-I facility.
Represents the 184th ANDA approval for the Eugia Pharma Specialities Group.
Product is bioequivalent and therapeutically equivalent to the reference drug Zortress by Novartis.
💼 Action for Investors
Investors should monitor the timely launch in Q1FY27 as this adds to Aurobindo's specialty portfolio in the US market. The approval reinforces the company's execution capabilities in the complex generics and specialty segment through its subsidiary Eugia.
Loading analysis...
Aurobindo Pharma Incorporates New Subsidiary Engenra Biologics for CDMO Expansion
Aurobindo Pharma has incorporated a new wholly-owned subsidiary, Engenra Biologics Private Limited, in India on February 24, 2026. The subsidiary is established with an initial cash subscription of Rs. 10 lakhs, representing 1,00,000 equity shares at Rs. 10 each. The primary objective of this new entity is to expand the company's contract manufacturing (CDMO) and other pharmaceutical manufacturing operations. This move signals Aurobindo's intent to scale its specialized manufacturing capabilities within the domestic market.
Key Highlights
Incorporation of Engenra Biologics Private Limited as a 100% wholly-owned subsidiary
Initial capital investment of Rs. 10 lakhs divided into 1,00,000 equity shares
Strategic focus on expanding contract manufacturing and pharmaceutical operations
Entity incorporated in India with 100% control and no prior turnover history
Transaction conducted at arms-length with no promoter group interest
💼 Action for Investors
Investors should monitor the scale of capital expenditure and future contract wins under this new subsidiary as it indicates Aurobindo's growth trajectory in the CDMO space. The stock remains a watch for long-term expansion in specialized manufacturing.
Loading analysis...
Aurobindo Pharma Receives ₹169.84 Crore GST Demand and Penalty Order
Aurobindo Pharma has been served with four orders from the GST Department demanding the recovery of ₹169.84 crores in previously granted refunds. The demand includes ₹84.92 crores in GST and an equivalent penalty of ₹84.92 crores for the period of September to December 2022. The dispute involves the calculation of Input Tax Credit (ITC) refunds for its EOU Unit 3, which the department alleges were erroneous. The company intends to contest this demand through an appeal, stating that there is no material impact on its current operations.
Key Highlights
Total disputed amount stands at ₹169.84 crores, including a 100% penalty of ₹84.92 crores.
The orders allege erroneous refund of accumulated ITC under Rule 89 of CGST Rules for late 2022.
The dispute centers on whether domestic market values of similar goods should limit export refund amounts.
Aurobindo Pharma is challenging the validity of Rule 89(4)(C) in the Telangana High Court.
The company will file a fresh appeal before the Commissioner of Central Tax (Appeals), Hyderabad.
💼 Action for Investors
Investors should monitor the legal proceedings as tax disputes are common in the sector; however, the immediate financial impact is limited given the company's scale. No immediate action is required as the company is actively contesting the demand.
Loading analysis...
Aurobindo Pharma Clarifies USFDA Inspection at Unit-VII Following Media Reports
Aurobindo Pharma has issued a clarification to the stock exchanges regarding news reports of USFDA quality concerns at its Telangana-based Unit-VII. The company confirmed that the USFDA inspection at this facility concluded on February 10, 2026, and they are currently preparing a response to the observations within the stipulated timelines. Management maintains that these inspections are a routine part of global business operations and that all material information has already been disclosed. The stock had previously reacted to reports of these quality concerns, prompting the exchange's request for verification.
Key Highlights
USFDA inspection at Unit-VII (Telangana) was completed on February 10, 2026
Company responded to NSE and BSE clarification requests on February 18, 2026
Management committed to responding to USFDA observations within the required regulatory timeframe
Company asserts that no additional material information remains undisclosed beyond the February 10 filing
💼 Action for Investors
Investors should wait for details regarding the specific nature and severity of the USFDA observations (Form 483) for Unit-VII. The stock is likely to remain under pressure or volatile until the regulatory risk is fully quantified.
Loading analysis...
Aurobindo Pharma Q3 FY26: Revenue Up 8.4% to ₹8,646 Cr, Europe Growth Surges 27%
Aurobindo Pharma reported a steady Q3 FY26 with consolidated revenue growing 8.4% YoY to ₹8,646 crores, driven by a robust 27% growth in the European business. EBITDA margins remained healthy at 20.5%, supported by lower raw material costs and a favorable business mix. The company is on track for its Pen-G plant ramp-up, targeting over 10,000 metric tonnes annually, and expects its European operations to surpass the $1 billion mark by the end of FY26. Management clarified that recent USFDA observations at the Eugia III facility are procedural and will not impact production.
Key Highlights
Consolidated revenue increased 8.4% YoY to ₹8,646 crores with EBITDA at ₹1,773 crores (20.5% margin)
European formulation business grew 27% YoY to ₹2,703 crores, nearing a $1 billion annual run rate
US injectable sales rose 17% YoY, while overall US revenue stood at $420 million
Pen-G facility ramp-up is on track to reach 65-70% capacity by March 2026
Net profit reached ₹910 crores, despite a one-time ₹65 crore charge for labor code amendments
💼 Action for Investors
Investors should monitor the ramp-up of the Pen-G facility and the commercialization of the Dayton plant in FY27 as key margin drivers. The stock remains a strong play on geographic diversification, particularly with the outperformance in Europe.
Loading analysis...
Aurobindo Pharma Subsidiary Receives US FDA Approval for ADQUEY Ointment
Aurobindo Pharma's step-down subsidiary, Acrotech Biopharma, has secured US FDA approval for ADQUEY (difamilast 1%) ointment. This non-steroidal treatment is indicated for mild-to-moderate atopic dermatitis in adults and pediatric patients aged 2 and older. The approval is backed by Phase III clinical trials showing significant improvement in patients over a 4-week treatment period compared to a placebo. This marks a strategic milestone for Aurobindo as it expands its proprietary medication portfolio in the high-value US dermatology market.
Key Highlights
FDA approval granted for ADQUEY (difamilast 1%) for treating mild-to-moderate atopic dermatitis.
Indicated for both adults and pediatric patients as young as 2 years old.
Product is a novel, non-steroidal, topical phosphodiesterase 4 (PDE4) inhibitor.
Phase III trials demonstrated Investigator’s Global Assessment (IGA) success within 4 weeks of treatment.
Acrotech Biopharma has held the US license for this Otsuka Pharmaceutical-developed drug since 2021.
💼 Action for Investors
Investors should view this as a positive development that strengthens Aurobindo's specialty branded portfolio in the US. Monitor the commercial launch timeline and market penetration, as branded products typically offer higher margins than generic counterparts.
Loading analysis...
Aurobindo Pharma Unit-VII Receives US FDA Form 483 with 9 Procedural Observations
The US FDA concluded an inspection of Aurobindo Pharma's Unit-VII, an oral solid dosage manufacturing facility in Telangana, on February 10, 2026. The inspection, which began on January 28, resulted in the issuance of a Form 483 with 9 observations. Management has characterized these observations as procedural in nature and stated there is no immediate impact on financial or operational activities. The company is preparing a formal response to be submitted within the stipulated regulatory timelines.
Key Highlights
US FDA inspection conducted at Unit-VII oral solid dosage facility from January 28 to February 10, 2026.
Form 483 issued by the regulator containing a total of 9 observations.
Company management confirms all 9 observations are procedural in nature.
No immediate quantifiable financial or operational impact reported by the company.
Unit-VII is located at the Special Economic Zone (Pharma) in Jedcherla, Telangana.
💼 Action for Investors
Investors should monitor the final classification of the inspection by the US FDA, as 9 observations is a significant count even if procedural. Watch for updates on whether the facility receives Voluntary Action Indicated (VAI) or Official Action Indicated (OAI) status.